> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# The First Authorized Treatment for Negative Schizophrenia Symptoms Is Not a Pill
- URL: https://bioweek.com/the-first-authorized-treatment-for-negative-schizophrenia-symptoms-is-not-a-pill/
- Published: 2026-10-06T05:05:05.000Z
- Updated: 2026-10-07T05:07:16.000Z
- Description: FDA cleared Motivista as the first authorized treatment for negative symptoms of schizophrenia, but the pivotal trial showed a small-to-moderate effect against a control arm that also improved. The open question is whether payers will cover an app.
- Author: BioWeek
- Tags: Pipeline, Policy

For seven decades, antipsychotic drugs have chipped away at the hallucinations and delusions that define schizophrenia in the public imagination. The symptoms that most often keep people from working, dating, and living independently have had no indicated treatment at all. That changed this fall, and the treatment that filled the gap is a prescription app.

Click Therapeutics announced on October 5, 2026 that the FDA had cleared Motivista (CT-155) as the first authorized treatment indicated specifically for negative symptoms of schizophrenia. The [clearance](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K254038&ref=bioweek.com) itself dates to July 30, 2026, when the agency granted a traditional 510(k) for a "Computerized Behavioral Therapy Device For Depressive Disorders" under number K254038\. The device is prescribed as an adjunct to clinician-managed outpatient care, including antipsychotic therapy, for adults 18 and older with clinically stable positive symptoms.

### The symptom cluster drugs never touched

Negative symptoms, which include avolition, anhedonia, and asociality, affect roughly 60% of people living with schizophrenia, according to Click. The company estimates about 3.7 million adults in the United States and some 24 million people worldwide live with the condition. These symptoms are among the most disabling aspects of the illness, and no antipsychotic has ever carried an indication for them. The first authorization to arrive for that gap came not through the drug pathway but through the device side of the FDA, a route Akili Interactive's EndeavorRx took for pediatric ADHD back in 2020.

Motivista was developed by Click Therapeutics together with Boehringer Ingelheim, which funded the pivotal CONVOKE trial. The FDA granted the program Breakthrough Device Designation in 2024, signaling the agency saw the unmet need as serious enough to accelerate review.

### What the pivotal trial actually showed

CONVOKE (NCT05838625) was a Phase 3, multicenter, randomized, double-blind, 16-week study pitting CT-155 against a digital control app, both as adjuncts to antipsychotic therapy, in 457 adults stable on antipsychotics. Results [published](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2854497?ref=bioweek.com) in JAMA Network Open on September 25, 2026 showed that at week 16, CT-155 reduced the mean CAINS-MAP total score by 6.8 points (n=196) versus 4.2 points for the digital control (n=204). The least-squares difference was -2.6 (95% CI -4.0 to -1.2), with P<.001 and a Cohen d of -0.36.

JAMA's own conclusion frames the benefit as a small-to-moderate effect size comparable with psychosocial interventions and pharmacologic treatment in psychiatry, and describes the product as well tolerated and safe. On safety, serious adverse events occurred in 3 of 228 (1.3%) CT-155 participants versus 5 of 231 (2.2%) controls during the 16-week intervention and 4-week follow-up, none judged treatment related. The company's release does note two "psychotic disorder" events considered possibly related to Motivista in a single participant; neither led to discontinuation.

### The engagement question and the payer question

Digital therapeutics live or die on whether patients keep using them, and the trial data offer a cautionary note. Just 70.4% of CT-155 users stayed active through week 15, and participants completed activities on a median of 76 of 112 possible study days. In a clinical trial, with monitoring and compensation, engagement already trailed off. The effect size in real-world use, where adherence typically falls below trial conditions, could shrink further.

Then there is the commercial question. A benefit measured in single-digit scale points, against a control arm that also improved 4.2 points, asks payers to fund software whose incremental value is real but modest. In CONVOKE itself, 80% of participants were unemployed, a reminder of how much of the population involved sits inside safety-net coverage. Click's chief commercial officer pointed to state Medicaid programs, and whether those programs, already strained, will pay for an app-based adjunct is the question that will decide whether Motivista becomes standard of care or a niche offering.

The significance here is less about any single effect size and more about precedent. The most disabling dimension of schizophrenia just got its first authorized treatment, delivered through a regulatory pathway originally built for hardware. Drug developers chasing negative symptoms for decades now have a benchmark, and an unexpected one, to beat.